By Ben Glickman
Amgen has received priority review status from the Food and Drug Administration for its biologics license application for a small cell lung cancer treatment.
The Thousand Oaks, Calif.-based pharmaceutical company will get an answer from the FDA on its application in six months, instead of the typical 10 months.
Amgen's BLA is for tarlatamab, a treatment for advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy.
The application is based on the results from a Phase 2 study.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
12-13-23 1625ET